Tag Archives: White House

Sequestration: How Big a Hit for FDA, Research and Pharma?

By Jill Wechsler | Published: March 12, 2013
The greatly feared federal budget sequestration mandate went into effect March 1, and, initially, the impact was fairly muted. The stock market soared, employment rose and government workers continued on their jobs. Federal agencies, including the Food and Drug Administration (FDA), launched initiatives to comply with the mandated 5% across-the-board cut in spending (in reality [...]
Posted in FDA, Legal, R&D, healthcare, leadership | Also tagged , , , , , , | Leave a comment

Will Healthcare Reform Pay Off?

By George Koroneos | Published: August 20, 2009
Written by Jordan Melnick Members of Congress are in for a hard landing when they get back from recess in early September. After four weeks at home in their districts, the debate will heat up again as they resume the arduous process of crafting the biggest piece of President Obama’s domestic agenda. With the president demanding [...]
Posted in Regulatory | Also tagged , , , , , , | Leave a comment

Tauzin to Boehner: Don’t “Bully” Me

By Walter Armstrong | Published: August 19, 2009
Image via Wikipedia PhRMA chief Billy Tauzin so far shows no sign of waving the white flag in response to an accusatory missive from House Minority Leader Rep. John Boehner bludgeoning his former Republican colleague for leading the drug industry’s support of President Obama’s healthcare reform effort. Pointedly CC’d to pharma CEOs – Tauzin’s employers—and simultaneously [...]
Posted in Regulatory | Also tagged , , , , , , | Leave a comment